OR WAIT 15 SECS
Despite Mexico’s efforts to improve its regulatory framework and create a better business environment for pharma.
Despite Mexico’s efforts to improve its regulatory framework and create a better business environment for pharma, the market share of generic drugs still makes it difficult for multinationals to materialize their commercial benefit. However, a new report from Business Monitor forecasts that, in the long term, Mexico’s improving private health insurance sector and potentially significant investment from the government will boost patented drug consumption in the country.
Business Monitor’s Mexico Pharmaceuticals & Healthcare Report outlines the following key trends and developments over the last few months:
Business Monitor forecasts real GDP growth in Mexico to accelerate from 1.5% in 2013 to 3.5% in 2014, amid an acceleration in household spending growth and an improvement in investment, bolstered by a successful reform drive in 2013. Exports will also pick up this year as US demand for manufacturing exports strengthens, the report states.